Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

https://www.soho2020.com/

 

MDS and MPN
09:07

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on MDS: Characteristics and Outcomes of SF3B1 Mutation in t-MDS vs. De Novo MDS, SF3B1 Mutation vs. SF3B1-WT in Therapy Related MDS

FEATURING Virginia Volpe
  • 164 views
  • December 11, 2020
14:48

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on IDH Inhibitors in MDS: How Common Are IDH 1/2 Mutations in MDS & What Are They Associated With? Is There Any Activity With Ivosidenib and Enasidenib?

FEATURING Courtney D. DiNardo
  • 17 views
  • December 11, 2020
13:30

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on Anemia in MDS: How Does Luspatercept Affect RBC-TI? What Is the Treatment Response With Novel Agent Imetelstat?

FEATURING Uwe Platzbecker
  • 154 views
  • November 9, 2020
  • 1
15:33

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on Oral HMAs in MDS: Can FDA-Approved Decitabine/Cedazuridine (ASTX727) Combo Be Used as an Alternative to IV Decitabine? Does Oral CC-486 Maintenance Therapy Improve Survival?

FEATURING Guillermo Garcia-Manero
  • 165 views
  • November 9, 2020
15:52

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on MDS: What Is the Safety and Efficacy of Ven+Aza Combo in Treatment-Naïve Patients? How Well Is It Tolerated in HR- & R/R Disease?

FEATURING Amer Zeidan
  • 127 views
  • November 9, 2020
  • 1
17:02

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on TP53 in MDS: What Is the Correlation of VAF and OS? Is Magrolimab+AZA Combo Beneficial for Response?

FEATURING David Sallman
  • 139 views
  • November 9, 2020
18:11

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on MDS: How Do TP53 Mutations Impact Prognosis in MDS? What Is the Effect of HMA and Allo-HCT on OS? Does Magrolimab+AZA Combo Eliminate Mutational Burden?

FEATURING David Sallman
  • 15 views
  • October 29, 2020
19:05

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on ET: What Does the Diagnostic Algorithm Look Like? How to Manage Different Risk Levels of the Disease?

FEATURING Ayalew Tefferi
  • 76 views
  • October 29, 2020
09:44

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

Next Questions in MF in 2020: What Is MIPSS70-Plus Risk Score? What Are the Most Important Novel Single Agent Trials?

FEATURING Prithviraj Bose
  • 24 views
  • October 29, 2020
10:10

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on MDS: What Is the Proposed Treatment Algorithm for 2020? What Are the New Approaches for Anemia?

FEATURING Guillermo Garcia-Manero
  • 21 views
  • October 29, 2020
16:23

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Highlights on Myelofibrosis: What Is the Distinctive Feature of MPN Pathogenesis? What Are the Prognostic Implications of Most Common Mutations? How Essential Is the Assessment of the Genomic Profile?

FEATURING Raajit Rampal
  • 358 views
  • October 20, 2020
  • 2
12:50

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Highlights on Myelofibrosis: How Can We Improve Survival After Transplant?

FEATURING Uday Popat
  • 151 views
  • October 20, 2020
  • 1
09:59

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on Myelofibrosis: What Are the Long-Term Outcomes of AlloSCT With Bu-Flu Regimen?

FEATURING Jacinth Joseph
  • 104 views
  • October 19, 2020
  • 1
17:07

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

73 y/o Male With Polycythemia Vera With JAK2 V617F Mutation: How Does PV Progress to MF? Does Inflammation Correlate with MPN Development?

FEATURING Laura Michaelis
  • 65 views
  • October 19, 2020
15:11

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

34 y/o Female With JAK2 V617F Mutated Polycythemia Vera: What PV Treatment Should Be Considered? How Can We Identify the Risks?

FEATURING Gabriela Hobbs
  • 181 views
  • October 19, 2020
  • 1
16:58

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on Myelofibrosis: What Are the Response Rates With Luspatercept? How Does Navitoclax/Ruxolitinib Combo Affect Spleen Volume? Is Imetelstat Beneficial for OS?

FEATURING Srdan Verstovsek
  • 157 views
  • October 19, 2020
  • 1